secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2022-03-22T23:59:59+00:00
Accession:  0001628280-22-006886
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen reports FY 2021 revenue up 15% to $48.3M; guides FY 2022 revenue $51-53M
-------------------------------------------------------------------------------

- Record 128,246 AVISE CTD tests in 2021; Q4 2021 test volume 34,147 (+21% YoY).
- Full-year testing revenue $47.1M (+27.8% YoY); Q4 testing revenue $12.5M (+14.2% YoY).
- FY 2021 net loss $26.9M vs $16.7M in 2020; cash $99.4M at year-end.
- Guidance: FY 2022 revenue $51M-$53M, implying 6-10% growth over 2021.
- Added Centene/WellCare coverage for 22M lives; now 91M in-network lives; acquired AVISE RADR license.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000162828022006886/0001628280-22-006886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000162828022006886/exdx-20220322.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-006886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer